Abstract
Summary
The global in vitro diagnostics market is projected to reach USD 119.4 billion by 2029 from USD 85.2 billion in 2024, at a CAGR of 6.9% during the forecast period. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. Chronic conditions that include diabetes, cancer, and cardiovascular disease are more common in old age. As these diseases need to be continuously monitored and managed, there is an increasing need for diagnostic tests. Also, due to a weakened immune system, people get increasingly susceptible to several infectious diseases. Effective treatment of infectious diseases depends on early detection, which made possible by IVD tests. Hence, this factor is significantly inducing growth of the IVD market.
“Molecular diagnostics (MDx) segment is projected to witness highest growth rate in the in vitro diagnostics market, by technology, during the forecast period.”
Based on the technology the IVD market is bifurcated into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and chromatography & mass spectrometry. The molecular diagnostics (MDx) segment is estimated to register the highest growth rate during the forecast period. Growth in this market is majorly driven by the rising prevalence of infectious diseases, cancer, and various genetic disorders; growing demand for blood screening; and increasing applications of molecular diagnostic technologies in pharmacogenetics and point-of-care testing.
“Endocrinology segment is projected to register highest growth rate in the in vitro diagnostics market, by application, during the forecast period.”
The IVD market is bifurcated into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The endocrinology segment is expected to grow at the highest rate within the in vitro diagnostics market. Technological advancements, the increasing incidence of diabetes and thyroid disorders, changing lifestyles, and the availability of home tests to control these medical conditions are the major drivers for the growth of the IVD market for endocrinology applications.
“Asia Pacific: The fastest-growing region in vitro diagnostics market.”
The global IVD market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. The Asia Pacific market is estimated to witness the highest growth rate during the forecast period. The rising healthcare spending, rapidly growing geriatric populations, and increasing disposable income make this region a lucrative market for growth opportunities.
The break-up of the profile of primary participants in the IVD market:
• By Company Type: Tier 1 - 42%, Tier 2 - 30%, and Tier 3 – 28%
• By Designation: C-level - 46%, D-level - 23%, and Others - 31%
• By Region: North America - 23%, Europe - 45%, Asia Pacific – 28.3%, Latin America- 3%, Middle East & Africa – 0.8%, GCC Countries – 1.3%
The key players in this market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Qiagen N.V. (Netherlands), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Revvity (US), Griffols (Spain), Werfen (Spain), Devyser (Sweden), Chembio Diagnostics, Inc. (US). Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), Caris Life Sciences, Inc (US), Cellabs (Australia), J. Mitra & Co. Pvt. Ltd. (India), Epitope Diagnostics (US), Boster Biological Technology (US), Enzo Biochem (US), Genetic Signatures (Australia), Savyon Diagnostics (Israel), Trivitron Healthcare (India), mdxhealth (Belgium), Creative Diagnostics (US), InBios International, Inc. (US), Maccura Biotechnology Co., Ltd. (China), Vela Diagnostics (Singapore), and ARKRAY, Inc. (Japan)
Research Coverage:
This research report divided the in vitro diagnostics market by test type (PoC tests and laboratory tests), by technology (molecular diagnostics, immunoassays, coagulation & hemostasis, clinical chemistry, urinalysis, chromatography & mass spectrometry, microbiology, and hematology), by product & services (instruments, reagents & kits, and data management software and services), specimen (urine, saliva, blood, serum, and plasma, and other specimens), by end user (pharmaceutical & biotechnology companies, hospital & clinics, blood banks, academic institutes, clinical laboratories, home care settings, and other end users), by application (endocrinology, cardiology, blood screening, blood group typing, autoimmune diseases, bone & mineral disorders, oncology, coagulation testing, genetic testing, infectious diseases, allergy diagnostics, drug monitoring & testing, and other applications), and by region (Latin America, the GCC Countries, Europe, Middle East & Africa, Asia Pacific, and North America)
The report's coverage includes comprehensive details about the key factors impacting the growth of the IVD market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, products offered, significant strategies, acquisitions and partnerships, product launches, and recent developments related to the IVD market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging in vitro diagnostics startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall in vitro diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers: (Increasing geriatric population and subsequent rise in chronic & infectious diseases, and Emergence of rapid PoC diagnostics), restraints (Unfavorable reimbursement scenario for IVD market), opportunities (Introduction of disease-specific biomarkers and tests, and Growth opportunities in emerging markets), and challenges (Operational barriers to the IVD market) influencing the growth of the in vitro diagnostics market.
• Product Development/Innovation: Detailed insights on research & development activities, and new product launches and approvals in the in vitro diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the in vitro diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US) among others in the IVD market strategies.
Table of Contents
1 INTRODUCTION 82
1.1 STUDY OBJECTIVES 82
1.2 MARKET DEFINITION 82
1.3 INCLUSIONS & EXCLUSIONS 83
1.4 MARKET SCOPE 84
1.4.1 MARKETS COVERED 84
1.4.2 REGIONS COVERED 85
1.4.3 YEARS CONSIDERED 85
1.4.4 CURRENCY CONSIDERED 86
1.5 MARKET STAKEHOLDERS 86
1.6 SUMMARY OF CHANGES 86
1.6.1 MARKET RECONCILIATION: 87
1.7 RECESSION IMPACT 87
2 RESEARCH METHODOLOGY 88
2.1 RESEARCH DATA 88
2.1.1 SECONDARY RESEARCH 89
- 2.1.1.1 Key data from secondary sources 90
2.1.2 PRIMARY DATA 90
- 2.1.2.1 Primary sources 91
- 2.1.2.2 Key data from primary sources 91
- 2.1.2.3 Key industry insights 93
2.2 MARKET SIZE ESTIMATION 94
2.2.1 BOTTOM-UP APPROACH 94
- 2.2.1.1 Approach 1: Company revenue estimation approach 95
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 98
2.4 MARKET SHARE ANALYSIS 99
2.5 STUDY ASSUMPTIONS 99
2.6 GROWTH RATE ASSUMPTIONS 99
2.7 RESEARCH LIMITATIONS 99
2.7.1 METHODOLOGY-RELATED LIMITATIONS 99
2.7.2 SCOPE-RELATED LIMITATIONS 100
2.8 RISK ASSESSMENT 100
2.9 RECESSION IMPACT ANALYSIS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 107
4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 107
4.1.7 HOLOGIC, INC 597
4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023) 108
4.3 IN VITRO DIAGNOSTICS MARKET: REGIONAL MIX 108
4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 109
4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED ECONOMIES 110
5 MARKET OVERVIEW 111
5.1 INTRODUCTION 111
5.2 MARKET DYNAMICS 111
5.2.1 DRIVERS 112
- 5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases 112
- 5.2.1.2 Gradual shift from centralized testing to point-of-care testing 113
- 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies 114
- 5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers 115
- 5.2.1.5 Growing preference for personalized medicine 115
- 5.2.1.6 Increasing funding for R&D activities 116
5.2.2 RESTRAINTS 116
- 5.2.2.1 Unfavorable reimbursements 116
- 5.2.2.2 Stringent regulatory requirements 117
- 5.2.2.3 High cost of diagnostic equipment 118
5.2.3 OPPORTUNITIES 118
- 5.2.3.1 Introduction of disease-specific biomarkers and tests 118
- 5.2.3.2 Growing significance of companion diagnostics 119
- 5.2.3.3 Growth opportunities in emerging markets 120
- 5.2.3.4 Improvements in immunoassay diagnostic technologies 121
- 5.2.3.5 Trend of digitalization 121
5.2.4 CHALLENGES 122
- 5.2.4.1 Operational barriers 122
5.3 PRICING ANALYSIS 123
5.3.1 INDICATIVE AVERAGE SELLING PRICE OF REAGENTS & KITS (USD), BY REGION 123
5.3.2 AVERAGE SELLING PRICE OF IMMUNOASSAY ANALYZERS (USD) 123
5.3.3 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS (USD) 124
5.3.4 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS (USD) 124
5.3.5 AVERAGE SELLING PRICE OF CLINICAL CHEMISTRY ANALYZERS (USD) 125
5.4 VALUE CHAIN ANALYSIS 126
5.5 SUPPLY CHAIN ANALYSIS 127
5.6 PORTER’S FIVE FORCES ANALYSIS 128
5.6.1 INTENSITY OF COMPETITIVE RIVALRY 129
5.6.2 BARGAINING POWER OF SUPPLIERS 129
5.6.3 BARGAINING POWER OF BUYERS 129
5.6.4 THREAT OF NEW ENTRANTS 129
5.6.5 THREAT OF SUBSTITUTES 129
5.7 ECOSYSTEM ANALYSIS 130
5.7.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 131
5.8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 131
5.9 REGULATORY ANALYSIS 132
5.9.1 NORTH AMERICA 132
- 5.9.1.1 US 132
- 5.9.1.2 Canada 134
5.9.2 EUROPE 134
5.9.3 ASIA PACIFIC 136
- 5.9.3.1 Japan 136
- 5.9.3.2 China 137
- 5.9.3.3 India 138
- 5.9.3.4 South Korea 138
- 5.9.3.5 Indonesia 139
5.9.4 RUSSIA 139
5.9.5 MIDDLE EAST & AFRICA 140
- 5.9.5.1 Saudi Arabia 140
- 5.9.5.2 Africa 141
5.9.6 LATIN AMERICA 141
- 5.9.6.1 Mexico 141
- 5.9.6.2 Brazil 142
5.10 PATENT ANALYSIS 143
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 145
5.11.1 REVENUE SHIFT FOR IN VITRO DIAGNOSTICS MARKET 145
5.12 KEY CONFERENCES & EVENTS 146
5.13 TECHNOLOGY ANALYSIS 146
5.13.1 IN VITRO DIAGNOSTICS MARKET: KEY TECHNOLOGIES 146
5.13.2 IN VITRO DIAGNOSTICS MARKET: ADJACENT TECHNOLOGIES 147
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 148
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 148
5.14.2 BUYING CRITERIA 149
5.15 TRADE ANALYSIS 150
5.15.1 TRADE ANALYSIS FOR IVD PRODUCTS 150
6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 151
6.1 INTRODUCTION 152
6.2 REAGENTS & KITS 152
6.2.1 INCREASING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET 152
6.3 INSTRUMENTS 156
6.3.1 RISING TREND OF AUTOMATION TO DRIVE MARKET 156
6.4 DATA MANAGEMENT SOFTWARE AND SERVICES 160
6.4.1 ABILITY TO IMPROVE OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH 160
7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 165
7.1 INTRODUCTION 166
7.2 IMMUNOASSAYS 166
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 171
- 7.2.1.1 Utilization in viral disease diagnostics and drug discovery to boost demand 171
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS 174
- 7.2.2.1 High sensitivity and wide detection range to fuel market 174
7.2.3 IMMUNOFLUORESCENCE ASSAYS 178
- 7.2.3.1 HIV antibody diagnosis in medical research to support market growth 178
7.2.4 RAPID TESTS 181
- 7.2.4.1 Rising usage in emergency care to drive market 181
7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT) 185
- 7.2.5.1 Rapid analysis of samples and high functionality to boost demand 185
7.2.6 WESTERN BLOTTING 188
- 7.2.6.1 Gold standard for result validation to boost demand 188
7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES 191
7.3 CLINICAL CHEMISTRY 194
7.3.1 BASIC METABOLIC PANELS 199
- 7.3.1.1 Rising prevalence of diabetes to boost demand 199
7.3.2 LIVER PANELS 202
- 7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to fuel market 202
7.3.3 RENAL PROFILES 205
- 7.3.3.1 Ability to monitor cytokines & chemokines in urine to propel market 205
7.3.4 LIPID PROFILES 208
- 7.3.4.1 Determination of total cholesterol and risk status for CVD to boost demand 208
7.3.5 THYROID FUNCTION PANELS 211
- 7.3.5.1 High incidence of thyroid-related disorders to support market growth 211
7.3.6 ELECTROLYTE PANELS 214
- 7.3.6.1 Ability to diagnose hypertension and heart failure to support uptake 214
7.3.7 SPECIALTY CHEMICAL TESTS 217
- 7.3.7.1 Inclusion of immunosuppressant drug monitoring and drugs of abuse to support market growth 217
7.4 MOLECULAR DIAGNOSTICS 220
7.4.1 POLYMERASE CHAIN REACTION (PCR) 225
- 7.4.1.1 High specificity of RT-PCR tests to drive market 225
7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 228
- 7.4.2.1 Cost benefits to drive market 228
7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 232
- 7.4.3.1 Declining costs of NGS-based tests to boost demand 232
7.4.4 IN SITU HYBRIDIZATION (ISH) 235
- 7.4.4.1 Rising prevalence of cancer and genetic disorders to drive market 235
7.4.5 DNA MICROARRAYS 238
- 7.4.5.1 High resolution and throughput capabilities to support market growth 238
7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 241
7.5 HEMATOLOGY 244
7.5.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST DEMAND 244
7.6 MICROBIOLOGY 247
7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET 247
7.7 COAGULATION & HEMOSTASIS 250
7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET 250
7.8 URINALYSIS 253
7.8.1 RISING INCIDENCE OF UTIS TO SUPPORT MARKET GROWTH 253
7.9 CHROMATOGRAPHY & MASS SPECTROMETRY 256
7.9.1 METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO FUEL MARKET 256
8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN 260
8.1 INTRODUCTION 261
8.2 BLOOD, SERUM, AND PLASMA 261
8.2.1 HIGH RELIABILITY FOR CHRONIC DISEASE DIAGNOSIS TO PROPEL MARKET 261
8.3 SALIVA 264
8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED TESTS TO SUPPORT MARKET GROWTH 264
8.4 URINE 267
8.4.1 INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND 267
8.5 OTHER SPECIMENS 270
9 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE 274
9.1 INTRODUCTION 275
9.2 LABORATORY TESTS 275
9.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET 275
9.3 POINT-OF-CARE TESTS 278
9.3.1 RAPID RESULTS AND HIGH CONVENIENCE TO BOOST DEMAND 278
10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION 282
10.1 INTRODUCTION 283
10.2 INFECTIOUS DISEASES 284
10.2.1 INCREASING PREVALENCE OF TB AND TYPHOID TO BOOST DEMAND 284
10.3 ONCOLOGY 287
10.3.1 HIGH INCIDENCE OF BREAST CANCER TO PROPEL MARKET 287
10.4 ENDOCRINOLOGY 290
10.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO DRIVE MARKET 290
10.5 CARDIOLOGY 293
10.5.1 INCREASING USE OF IMMUNOASSAYS IN CVD DETECTION TO FUEL MARKET 293
10.6 BLOOD SCREENING 297
10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT MARKET GROWTH 297
10.7 GENETIC TESTING 300
10.7.1 DIAGNOSIS OF RARE DISEASES TO SUPPORT MARKET GROWTH 300
10.8 AUTOIMMUNE DISEASES 303
10.8.1 GROWING DEMAND FOR AUTOIMMUNITY ASSAYS TO DRIVE MARKET 303
10.9 ALLERGY DIAGNOSTICS 306
10.9.1 ABILITY TO DETERMINE FOOD & DRUG ALLERGIES TO SUPPORT MARKET GROWTH 306
10.10 DRUG MONITORING & TESTING 309
10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 309
10.11 BONE & MINERAL DISORDERS 313
10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET 313
10.12 COAGULATION TESTING 317
10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO BOOST DEMAND 317
10.13 BLOOD GROUP TYPING 320
10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SUPPORT MARKET DEMAND 320
10.14 OTHER APPLICATIONS 323
11 IN VITRO DIAGNOSTICS MARKET, BY END USER 327
11.1 INTRODUCTION 328
11.2 HOSPITALS & CLINICS 328
11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND 328
11.3 CLINICAL LABORATORIES 332
11.3.1 LARGE REFERENCE LABORATORIES 335
- 11.3.1.1 Capability to conduct specific advanced tests to propel market 335
11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES 338
- 11.3.2.1 Growing focus on POC device adoption to support market growth 338
11.4 BLOOD BANKS 341
11.4.1 RISING UTILIZATION OF ELISA TESTS TO PROPEL MARKET 341
11.5 HOME CARE SETTINGS 344
11.5.1 ADOPTION OF CONVENIENT AT-HOME ANTIGEN TESTS TO BOOST DEMAND 344
11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 348
11.6.1 INCREASING FOCUS ON DRUG DISCOVERY DEVELOPMENT TO DRIVE MARKET 348
11.7 ACADEMIC INSTITUTES 351
11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH 351
11.8 OTHER END USERS 354
12 IN VITRO DIAGNOSTICS MARKET, BY REGION 358
12.1 INTRODUCTION 359
12.2 NORTH AMERICA 360
12.2.1 NORTH AMERICA: RECESSION IMPACT 360
12.2.2 US 367
- 12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market 367
12.2.3 CANADA 373
- 12.2.3.1 Favorable funding initiatives for early disease diagnosis to drive market 373
12.3 EUROPE 380
12.3.1 EUROPE: RECESSION IMPACT 381
12.3.2 GERMANY 388
- 12.3.2.1 Increasing investments in clinical diagnostics research to drive market 388
12.3.3 FRANCE 394
- 12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market 394
12.3.4 UK 399
- 12.3.4.1 Rising adoption of genome-based testing to drive market 399
12.3.5 ITALY 406
- 12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth 406
12.3.6 SPAIN 412
- 12.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market 412
12.3.7 RUSSIA 417
- 12.3.7.1 High incidence of respiratory infectious diseases to boost demand 417
12.3.8 SWITZERLAND 423
- 12.3.8.1 Rising prevalence of chronic diseases to support market growth 423
12.3.9 REST OF EUROPE 429
12.4 ASIA PACIFIC 436
12.4.1 ASIA PACIFIC: RECESSION IMPACT 444
12.4.2 JAPAN 444
- 12.4.2.1 Increasing research investments for immunoassays to drive market 444
12.4.3 CHINA 450
- 12.4.3.1 Growing focus on preventive care to boost demand 450
12.4.4 INDIA 455
- 12.4.4.1 Rising incidence of diabetes and cancer to drive market 455
12.4.5 SOUTH KOREA 461
- 12.4.5.1 Rising healthcare spending for innovative IVD technologies to support market growth 461
12.4.6 AUSTRALIA 467
- 12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market 467
12.4.7 REST OF ASIA PACIFIC 474
12.5 LATIN AMERICA 480
12.5.1 LATIN AMERICA: RECESSION IMPACT 480
12.5.2 BRAZIL 486
- 12.5.2.1 Rising prevalence of diabetes to boost demand for IVD products 486
12.5.3 MEXICO 491
- 12.5.3.1 Establishment of clinical laboratories to fuel uptake 491
12.5.4 REST OF LATIN AMERICA 497
12.6 MIDDLE EAST & AFRICA 503
12.6.1 GROWING FOCUS ON PRENATAL & CANCER TESTING TO DRIVE MARKET 503
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 508
12.7 GCC COUNTRIES 509
12.7.1 GCC COUNTRIES: RECESSION IMPACT 509
12.7.2 KINGDOM OF SAUDI ARABIA (KSA) 515
- 12.7.2.1 Rising government healthcare expenditure to boost demand 515
12.7.3 UNITED ARAB EMIRATES (UAE) 521
- 12.7.3.1 Improvements in healthcare infrastructure to support market growth 521
12.7.4 OTHER GCC COUNTRIES 527
13 COMPETITIVE LANDSCAPE 533
13.1 OVERVIEW 533
13.2 STRATEGIES ADOPTED BY KEY PLAYERS 533
13.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 535
13.4 MARKET SHARE ANALYSIS 536
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 538
13.5.1 STARS 538
13.5.2 EMERGING LEADERS 538
13.5.3 PERVASIVE PLAYERS 538
13.5.4 PARTICIPANTS 538
13.5.5 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS 540
13.6 START UP/SME EVALUATION MATRIX, 2023 544
13.6.1 PROGRESSIVE COMPANIES 544
13.6.2 RESPONSIVE COMPANIES 544
13.6.3 DYNAMIC COMPANIES 544
13.6.4 STARTING BLOCKS 544
13.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES 545
13.7 COMPETITIVE SCENARIO 546
13.7.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 546
13.7.2 DEALS 547
13.7.3 EXPANSIONS 548
13.7.4 OTHER DEVELOPMENTS 549
13.8 BRAND/PRODUCT COMPARISON 550
14 COMPANY PROFILES 551
14.1 KEY PLAYERS 551
14.1.1 DANAHER CORPORATION 551
14.1.2 ROCHE DIAGNOSTICS 558
14.1.3 ABBOTT 568
14.1.4 SIEMENS HEALTHINEERS AG 576
14.1.5 THERMO FISHER SCIENTIFIC INC 583
14.1.6 ILLUMINA, INC 591
14.1.8 BIO-RAD LABORATORIES, INC 601
14.1.9 BIOMÉRIEUX 606
14.1.10 SYSMEX CORPORATION 612
14.1.11 REVVITY 616
14.1.12 BECTON, DICKINSON AND COMPANY 622
14.1.13 AGILENT TECHNOLOGIES, INC 628
14.1.14 QIAGEN N.V 635
14.1.15 DIASORIN S.P.A 644
14.1.16 GRIFOLS S.A 652
14.1.17 WERFEN S.A 655
14.1.18 QUIDELORTHO CORPORATION 659
14.2 OTHER PLAYERS 666
14.2.1 DEVYSER 666
14.2.2 CHEMBIO DIAGNOSTICS, INC 668
14.2.3 SURMODICS, INC 671
14.2.4 MENARINI SILICON BIOSYSTEMS 674
14.2.5 SPEEDX PTY. LTD 675
14.2.6 GENSPEED BIOTECH GMBH 676
14.2.7 MERCK KGAA 677
14.2.8 CARIS LIFE SCIENCES, INC 679
14.2.9 ARKRAY, INC 681
14.2.10 ACCELERATE DIAGNOSTICS, INC 682
14.2.11 CELLABS 683
14.2.12 J. MITRA & CO. PVT. LTD 684
14.2.13 EPITOPE DIAGNOSTICS, INC 685
14.2.14 BOSTER BIOLOGICAL TECHNOLOGY 686
14.2.15 ENZO BIOCHEM, INC 687
14.2.16 GENETIC SIGNATURES 688
14.2.17 SAVYON DIAGNOSTICS LTD 689
14.2.18 TRIVITRON HEALTHCARE 690
14.2.19 MDXHEALTH SA 691
14.2.20 CREATIVE DIAGNOSTICS 692
14.2.21 INBIOS INTERNATIONAL, INC 693
14.2.22 MACCURA BIOTECHNOLOGY CO., LTD 694
14.2.23 VELA DIAGNOSTICS 695
15 APPENDIX 696
15.1 DISCUSSION GUIDE 696
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 703
15.3 CUSTOMIZATION OPTIONS 705
15.4 RELATED REPORTS 706
15.5 AUTHOR DETAILS 707